No abstract

1.1, p¼0.53). Furthermore, improved median PFS was seen in NLR-H patients treated with chemo/ICI compared to ICI-alone (HR 0.5, p¼0.05).Conclusions: Combination chemo/ICI therapy appears to overcome the poor survival driven by myeloid-mediated immunosuppression as manifested by NLR-H status. It provides a potential mechanism for the synergistic effect of chemo/ICI seen in clinical trials and supports the investigation of combination strategies that modulate the tumor-myeloid axis.Legal entity responsible for the study: The authors.

No abstract

No abstract